Viridian Therapeutics, Inc. (FRA:1S1)
26.49
-0.44 (-1.63%)
At close: Dec 19, 2025
Viridian Therapeutics Revenue
Viridian Therapeutics had revenue of $70.57M USD in the quarter ending September 30, 2025, with 81,958.14% growth. This brings the company's revenue in the last twelve months to $789.00K, up 161.26% year-over-year. In the year 2024, Viridian Therapeutics had annual revenue of $302.00K, down -3.82%.
Revenue (ttm)
$789.00K
Revenue Growth
+161.26%
P/S Ratio
43.09
Revenue / Employee
$5.52K
Employees
143
Market Cap
2.60B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 302.00K | -12.00K | -3.82% |
| Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
| Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
| Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
| Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
| Dec 31, 2019 | 4.46M | -3.93M | -46.80% |
| Dec 31, 2018 | 8.39M | 4.38M | 109.49% |
| Dec 31, 2017 | 4.00M | 526.00K | 15.13% |
| Dec 31, 2016 | 3.48M | 939.00K | 37.00% |
| Dec 31, 2015 | 2.54M | -1.78M | -41.25% |
| Dec 31, 2014 | 4.32M | 4.00K | 0.09% |
| Dec 31, 2013 | 4.32M | -90.04K | -2.04% |
| Dec 31, 2012 | 4.41M | 2.49M | 130.01% |
| Dec 31, 2011 | 1.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Deutsche Post AG | 84.05B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
Viridian Therapeutics News
- 6 days ago - Viridian Therapeutics (VRDN) Sees 5% Stock Increase - GuruFocus
- 6 days ago - Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
- 6 days ago - Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
- 11 days ago - VRDN: Wedbush Raises Price Target to $47 While Maintaining Outperform Rating | VRDN Stock News - GuruFocus
- 16 days ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - William Blair Initiates Coverage on Viridian Therapeutics (VRDN) with Outperform Rating | VRDN ... - GuruFocus
- 27 days ago - Truist Securities Initiates Coverage on VRDN with Buy Rating | VRDN Stock News - GuruFocus
- 6 weeks ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Wallstreet:Online